News

Cigna takes different approach with GLP-1s, more favorable for Eli Lilly
Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly ...
Modern Healthcare1d
Cigna debuts GLP-1 copay cap
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...
Endpoints News3h
Cigna, No­vo of­fer low­er GLP-1 prices to lure pa­tients to brand-name drugs
Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...
GlobalData on MSN8h
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month
Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...